Scharrer I - Search Results

1

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Scandella DH, Nakai H, Felch M, Mondorf W, Scharrer I, Hoyer LW, Saenko EL. Scandella DH, et al. Among authors: scharrer i. Thromb Res. 2001 Mar 1;101(5):377-85. doi: 10.1016/s0049-3848(00)00418-7. Thromb Res. 2001. PMID: 11297754

2

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. Prescott R, et al. Among authors: scharrer i. Blood. 1997 May 15;89(10):3663-71. Blood. 1997. PMID: 9160671 Free article.

3

Lack of inhibitor to monoclonal-antibody purified FVIII concentrate.

Mondorf W, Scharrer I. Mondorf W, et al. Among authors: scharrer i. Lancet. 1990 Sep 22;336(8717):747. doi: 10.1016/0140-6736(90)92240-i. Lancet. 1990. PMID: 1975915 No abstract available.

4

Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay.

Mondorf W, Ehrenforth S, Vigh Z, Last J, Tippmann G, Kreuz W, Scharrer I. Mondorf W, et al. Among authors: scharrer i. Vox Sang. 1994;66(1):8-13. doi: 10.1111/j.1423-0410.1994.tb00269.x. Vox Sang. 1994. PMID: 8146988

5

[Successful treatment of massive hemorrhagic diathesis caused by Factor VIII:C-antibodies with adsorption plasmapheresis and immunosuppression].

Mondorf W, Grützmacher P, Schmidt H, Wolff B, Scharrer I, von Baum H. Mondorf W, et al. Among authors: scharrer i. Med Klin (Munich). 1991 Mar 15;86(3):165-70, 171. Med Klin (Munich). 1991. PMID: 1903498 German. No abstract available.

6

A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.

Aygören-Pürsün E, Scharrer I. Aygören-Pürsün E, et al. Among authors: scharrer i. Thromb Haemost. 1997 Nov;78(5):1352-6. Thromb Haemost. 1997. PMID: 9408018 Clinical Trial.

7

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Abshire TC, et al. Among authors: scharrer i. Thromb Haemost. 2000 Jun;83(6):811-6. Thromb Haemost. 2000. PMID: 10896230 Clinical Trial.

8

Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.

Ehrenforth S, Kreuz W, Funk M, Auerswald G, Scharrer I. Ehrenforth S, et al. Among authors: scharrer i. Thromb Haemost. 1994 Nov;72(5):784-5. Thromb Haemost. 1994. PMID: 7900088 No abstract available.

9

Two years' experience with two recombinant factor VIII concentrates.

Brackmann HH, Aygören E, Scharrer I, Schwaab R, Hammerstein U, Oldenburg J. Brackmann HH, et al. Among authors: scharrer i. Blood Coagul Fibrinolysis. 1993 Jun;4(3):421-4. doi: 10.1097/00001721-199306000-00004. Blood Coagul Fibrinolysis. 1993. PMID: 8329567

10

Effects of human elastase on von Willebrand factor in highly purified factor VIII concentrate and in cryoprecipitate.

Jeleńska M, Bykowska W, Kopeć M, Vigh Z, Scharrer I, Breddin K. Jeleńska M, et al. Among authors: scharrer i. Thromb Res. 1990 Jul 15;59(2):295-307. doi: 10.1016/0049-3848(90)90132-v. Thromb Res. 1990. PMID: 2122538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters